Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
Vijaya Raj Bhatt1, Vamshi Balasetti2, Jagar A Jasem3
1Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
Insights
Central nervous system complications (CNSC) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly reduce patient survival. Early detection and management of CNSC are crucial for improving outcomes in these high-risk patients.
Area of Science:
- Hematology
- Neuroscience
- Transplantation Medicine
Background:
- Central nervous system complications (CNSC) are a significant cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Understanding the incidence and impact of CNSC is critical for improving patient outcomes.
Purpose of the Study:
- To determine the incidence of CNSC in patients undergoing allo-HSCT.
- To evaluate the impact of CNSC on patient survival.
Main Methods:
- Retrospective cohort study of patients with hematologic disorders who received allo-HSCT between 2002 and 2011.
- Analysis of CNSC incidence, types, and association with overall survival.
Main Results:
- 45 out of 351 patients (12.8%) developed CNSC.
- The most common CNSC included posterior reversible encephalopathy syndrome (40%), stroke (24%), and seizures (20%).
- Patients with CNSC had significantly lower 5-year overall survival (14% vs. 44%) and a higher risk of mortality (HR 1.56).
Conclusions:
- CNSC after allo-HSCT are associated with reduced survival.
- There is a need for improved risk identification, monitoring, and early management of CNSC to enhance outcomes.
Background:
Central nervous system complications (CNSC) can be the cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to determine the incidence of CNSC and its impact on survival.
Patients And Methods:
This retrospective cohort study included patients with hematologic disorders who received allo-HSCT between 2002 and 2011 at the University of Nebraska Medical Center.
Results:
Of the 351 patients identified, 45 developed CNSC (12.8%). The 100-day cumulative incidence of CNSC was 8% (95% confidence interval, 8-15). The most common CNSC included posterior reversible encephalopathy syndrome (40%), stroke or transient ischemic attack (24%), seizures (20%), and infection (9%). The 5-year overall survival was significantly lower among patients with versus without CNSC (14% vs. 44%, P = .0004). In multivariate analysis, the risk of mortality for patients with versus without CNSC was significantly higher (hazard ratio, 1.56; 95% confidence interval, 1.03-2.36; P = .04).
Conclusion:
The occurrence of CNSC after allo-HSCT was associated with reduced survival. Identifying patients at risk, monitoring, early detection, and management of CNSC after allo-HSCT are needed to improve outcomes.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:01Regulation of Hematopoietic Stem Cells
01:40Cell-mediated Immune Responses
01:21Lineage Commitment